David M. Routman

David M. Routman

Auto-generated profile, based on publicly available information

David M. Routman

Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2022 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
DRDavid M. Routman
David M. Routman
SKSunil Kumar
Sunil Kumar
BCBisham S. Chera
Bisham S. Chera
KJKrishan R. Jethwa
Krishan R. Jethwa
KAKathryn M. Van Abel
Kathryn M. Van Abel
DMDaniel J. Ma
Daniel J. Ma

14 February 2018 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
DRDavid M. Routman
David M. Routman
SBShelly X. Bian
Shelly X. Bian
KDKevin Diao
Kevin Diao
JLJonathan L. Liu
Jonathan L. Liu
CYCheng Yu
Cheng Yu
ECEric L. Chang
Eric L. Chang
Stereotactic Radiosurgery (SRS) is considered standard of care for patients with 1–3 brain metastases (BM). Recent observational studies have shown equivalent OS in patients with 5+ BM compared to those with 2–4, suggesting SRS alone may be appropriate in these patients. We aim to review outcomes of patients treated with SRS with 2–4 versus 5+ BM. This analysis included consecutive patients from 1994 to 2015 treated with SRS. Of 1017 patients, we excluded patients with a single BM and patients without adequate survival data, resulting in 391 patients. All risk factors were entered into univariate analysis using Cox proportional hazards model, and significant factors were entered into multivariate analysis (MVA). We additionally analyzed outcomes after excluding patients with prior surgery or whole‐brain radiotherapy (WBRT). Median follow‐up was 7.1 months. Median KPS was 90, mean age was 59, and most common histologies were melanoma and lung. Median tumor volume was 3.41 cc. Patients with 2–4 BM had a median OS of 8.1 months compared to 6.2 months for those with 5+ BM (P = 0.0136). On MVA, tumor volume, KPS, and histology remained significant for OS, whereas lesion number did not. Similar results were found when excluding patients with prior surgery or WBRT. Rather than lesion number, the strongest prognostic factors for patients undergoing SRS were tumor volume >10 cc, KPS, and histology. BM number may therefore not be the most important criterion for candidacy for SRS. Patients with 5 or more BM should be considered for SRS.

25 January 2022 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
RKRoman O. Kowalchuk
Roman O. Kowalchuk
BTBenjamin C. Kamdem Talom
Benjamin C. Kamdem Talom
KAKathryn M. Van Abel
Kathryn M. Van Abel
DMDaniel M. Ma
Daniel M. Ma
MWMark R. Waddle
Mark R. Waddle
DRDavid M. Routman
David M. Routman
Because of the favorable treatment outcomes for human papillomavirus (HPV)–associated oropharyngeal squamous cell cancer (OPSCC), efforts are ongoing to reduce the burden and cost of posttreatment surveillance. National Comprehensive Cancer Network (NCCN) guidelines recommend 1 imaging study (positron emission tomography/computed tomography [PET/CT] preferred) 8 to 12 weeks after completion of radiotherapy and/or chemotherapy, but additional imaging studies are commonly ordered.1 Circulating tumor DNA (ctDNA) has shown impressive predictive value in surveillance across multiple malignant neoplasms, with positive and negative predictive values of 94% and 100%, respectively, for HPV-associated OPSCC.2 We undertook a cross-sectional cost comparison of ctDNA utilization for posttreatment surveillance of HPV-associated OPSCC, which may offer equivalent or even improved accuracy compared with existing imaging strategies.

1 November 2017 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
DRDavid M. Routman
David M. Routman
RFRyan K. Funk
Ryan K. Funk
KTKanograt Tangsriwong
Kanograt Tangsriwong
ALAlexander Lin
Alexander Lin
MKMichael G. Keeney
Michael G. Keeney
DMDaniel J. Ma
Daniel J. Ma

23 December 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
CRCecile Riviere-Cazaux
Cecile Riviere-Cazaux
XDXiaoxi Dong
Xiaoxi Dong
WMWei Mo
Wei Mo
RKRahul Kumar
Rahul Kumar
CDChao Dai
Chao Dai
TBTerry C. Burns
Terry C. Burns
Purpose: Current methods for glioma response assessment are limited. This study aimed to assess the technical and clinical feasibility of molecular profiling using longitudinal intracranial cerebrospinal fluid (CSF) from patients with gliomas. Experimental Design: Adults with gliomas underwent longitudinal intracranial CSF collection via Ommaya reservoirs or ventriculoperitoneal shunts. Cell-free DNA (cfDNA) was extracted and analyzed using PredicineCARE for cancer variant profiling and/or PredicineSCORE for low-pass whole-genome sequencing. Results: Five patients (two females and three males; median age, 40 years; range, 32–64 years) underwent longitudinal intracranial CSF collection via Ommaya reservoirs (n = 4) or ventriculoperitoneal shunts (n = 1). In total, 47 CSF samples were obtained (median volume, 4.00 mL; 0.5–5 mL). Forty-one samples (87.2%) yielded sufficient cfDNA for testing. Patient-specific tumor-associated variant allelic frequencies (VAF), and thus tumor fraction, decreased in pre- versus postchemoradiation samples, including through pseudoprogression. These also increased with radiographic progression in three patients, although identifying the time of definitive disease progression from MRIs was a significant limitation. In two patients with isocitrate dehydrogenase (IDH)–mutant gliomas, decreasing IDH1 VAF after resection and chemoradiation correlated with decreased CSF D-2-hydroxyglutarate levels (0.64× and 0.62×, respectively, for the first patient and 0.01× and 0.07× for the other patient), although D-2-hydroxyglutarate and IDH1 VAF were not concordant in one patient thereafter. Moreover, the copy-number burden decreased below the limit of quantification during treatment and increased above the limit at progression. Conclusions: Longitudinal intracranial CSF cfDNA can be obtained in patients with gliomas during their disease course. However, before deploying this technique, numerous questions and challenges should be answered.